CYTR Key Stats
- CytRx Reports 2013 Financial Results noodls 03/05 06:16 ET
- CYTRX CORP Files SEC form 10-K, Annual Report Yahoo 03/05 06:01 ET
- CYTRX CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits Yahoo 03/05 06:01 ET
- Aegis Capital Keeps CytRx (CYTR) at Buy Following Recent Equity Raise Street Insider 02/18 07:57 ET
- CYTRX CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits Yahoo 02/13 16:26 ET
- Catasys Announces Transition to a New Board of Directors PR Newswire 02/13 09:00 ET
- CytRx Corporation (CYTR) Showing Signs Of A Dead Cat Bounce Today The Street 02/13 05:28 ET
- Galena Biopharma Pays For Stock-Touting Campaign While Insiders Cash Out Millions Yahoo 02/12 17:54 ET
- CytRx gets a vote of confidence Yahoo 02/07 09:34 ET
- CytRx Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares noodls 02/05 12:29 ET
CYTR Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). CytRx is up 102.0% over the last year vs S&P 500 Total Return up 24.21%, ImmunoCellular Therapeuti down 53.39%, and Galena Biopharma up 68.42%.
Income Statement View Statement
Balance Sheet View Statement
Pro Ratings for CYTR
Pro Strategies Featuring CYTR
Did CytRx make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
- Sector: Healthcare
- Industry: Biotechnology
- Headquarters Country: United States
- Headquarters State/Province: California
- Incorporation Country: United States
- Incorporation State/Province: Delaware
CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. Its oncology pipeline includes three clinical-stage drug candidates in various stages of development: Aldoxorubicin, Tamibarotene, and Bafetinib.